Keryx Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Boston MA United States (1997)
Status: Acquired by Akebia Therapeutics (2018)

Organization Overview

First Clinical Trial
2002
NCT00613093
First Marketed Drug
2014
ferric citrate (auryxia)
First NDA Approval
2014
ferric citrate (auryxia)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Keryx, | Keryx Biopharmaceuticals | KERYX BIOPHARMS

Active Ingredients

Marketed Drugs (1)

ferric citrate (auryxia) (2014 NDA)

Drugs in Phase 4 Trials (2)

ferric citrate (auryxia) (15 trials)

sulodexide (3 trials)

Drugs in Phase 3 Trials (2)

calcium (1 trial)

sevelamer (renagel) (1 trial)

Drugs in Phase 2 Trials (5)

Key: Keryx (0) Acquired (5)

bortezomib (velcade) (1 trial)

o6-benzylguanine (3 trials)

perifosine (6 trials)

temozolomide (temodar) (4 trials)

urea (1 trial)

Drugs in Phase 1 Trials (3)

docetaxel (taxotere) (1 trial)

gemcitabine (gemzar) (1 trial)

irinotecan (Camptosar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Anemia, Iron-Deficiency (Phase 4)

Brain Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 1)

Deficiency Diseases (Phase 3)

Diabetic Nephropathies (Phase 4)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Gliosarcoma (Phase 1)

Hyperphosphatemia (Phase 4)

Inflammation (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 1)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial APIs: 12